Interference with Activator Protein-2 transcription factors leads to induction of apoptosis and an increase in chemo- and radiation-sensitivity in breast cancer cells

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Thewes, Verena ^a,c   Orso, Francesca ^b   Jäger, Richard ^a,d   Eckert, Dawid ^a   Schäfer, Sabine ^a   Kirfel, Gregor ^a   Garbe, Stephan ^a   Taverna, Daniela ^b   Schorle, Hubert ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF TURIN   (Italy)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; MUTANT PROTEIN; TRANSCRIPTION FACTOR AP 2; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, MOUSE; ISOPROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL ADHESION; CELL COUNT; CELL DEATH; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; RADIOSENSITIVITY; UPREGULATION; ANIMAL; DNA MICROARRAY; DRUG EFFECT; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETIC DATABASE; GENETIC TRANSFECTION; GENETICS; METABOLISM; METHODOLOGY; MUTATION; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DATABASES, GENETIC; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ISOFORMS; RADIATION TOLERANCE; RECEPTOR, ERBB-2; TRANSCRIPTION FACTOR AP-2; TRANSFECTION;

EID: 77951965612     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-192     Document Type: Article

References (37)

1. Eckert D, Buhl S, Weber S, Jager R, Schorle H. The AP-2 family of transcription factors. Genome Biol 2005, 6(13):246. 10.1186/gb-2005-6-13-246, 1414101, 16420676.
2. Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 1996, 13(8):1701-1707.
3. Pellikainen JM, Kosma VM. Activator protein-2 in carcinogenesis with a special reference to breast cancer--a mini review. Int J Cancer 2007, 120(10):2061-2067. 10.1002/ijc.22648, 17330235.
4. Friedrichs N, Jager R, Paggen E, Rudlowski C, Merkelbach-Bruse S, Schorle H, Buettner R. Distinct spatial expression patterns of AP-2alpha and AP-2gamma in non-neoplastic human breast and breast cancer. Mod Pathol 2005, 18(3):431-438. 10.1038/modpathol.3800292, 15467710.
5. Friedrichs N, Steiner S, Buettner R, Knoepfle G. Immunohistochemical expression patterns of AP2alpha and AP2gamma in the developing fetal human breast. Histopathology 2007, 51(6):814-823. 10.1111/j.1365-2559.2007.02887.x, 18042070.
6. Hilger-Eversheim K, Moser M, Schorle H, Buettner R. Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene 2000, 260(1-2):1-12. 10.1016/S0378-1119(00)00454-6, 11137286.
7. Wajapeyee N, Britto R, Ravishankar HM, Somasundaram K. Apoptosis induction by activator protein 2alpha involves transcriptional repression of Bcl-2. J Biol Chem 2006, 281(24):16207-16219. 10.1074/jbc.M600539200, 16533807.
8. Wajapeyee N, Raut CG, Somasundaram K. Activator protein 2alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy. Cancer Res 2005, 65(19):8628-8634. 10.1158/0008-5472.CAN-05-1059, 16204029.
9. Zeng YX, Somasundaram K, el-Deiry WS. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet 1997, 15(1):78-82. 10.1038/ng0197-78, 8988173.
10. Gee JM, Robertson JF, Ellis IO, Nicholson RI, Hurst HC. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol 1999, 189(4):514-520. 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9, 10629551.
11. Piao Z, Lee KS, Kim H, Perucho M, Malkhosyan S. Identification of novel deletion regions on chromosome arms 2q and 6p in breast carcinomas by amplotype analysis. Genes Chromosomes Cancer 2001, 30(2):113-122. 10.1002/1098-2264(2000)9999:9999<::AID-GCC1069>3.0.CO;2-6, 11135428.
12. Zhang J, Brewer S, Huang J, Williams T. Overexpression of transcription factor AP-2alpha suppresses mammary gland growth and morphogenesis. Dev Biol 2003, 256(1):127-145. 10.1016/S0012-1606(02)00119-7, 12654297.
13. McPherson LA, Loktev AV, Weigel RJ. Tumor suppressor activity of AP2alpha mediated through a direct interaction with p53. J Biol Chem 2002, 277(47):45028-45033. 10.1074/jbc.M208924200, 12226108.
14. Pellikainen MJ, Pekola TT, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. J Clin Pathol 2003, 56(3):214-220. 10.1136/jcp.56.3.214, 1769912, 12610102.
15. Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW, Waldman FM. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 1994, 91(6):2156-2160. 10.1073/pnas.91.6.2156, 43329, 8134364.
16. Tanner MM, Tirkkonen M, Kallioniemi A, Collins C, Stokke T, Karhu R, Kowbel D, Shadravan F, Hintz M, Kuo WL, et al. Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res 1994, 54(16):4257-4260.
17. Gee JM, Eloranta JJ, Ibbitt JC, Robertson JF, Ellis IO, Williams T, Nicholson RI, Hurst HC. Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J Pathol 2009, 217(1):32-41. 10.1002/path.2430, 18825690.
18. Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M, Huebner K. Wwox and Ap2gamma expression levels predict tamoxifen response. Clin Cancer Res 2007, 13(20):6115-6121. 10.1158/1078-0432.CCR-07-1282, 17947476.
19. Williamson JA, Bosher JM, Skinner A, Sheer D, Williams T, Hurst HC. Chromosomal mapping of the human and mouse homologues of two new members of the AP-2 family of transcription factors. Genomics 1996, 35(1):262-264. 10.1006/geno.1996.0351, 8661133.
20. Jager R, Werling U, Rimpf S, Jacob A, Schorle H. Transcription factor AP-2gamma stimulates proliferation and apoptosis and impairs differentiation in a transgenic model. Mol Cancer Res 2003, 1(12):921-929.
21. Jager R, Friedrichs N, Heim I, Buttner R, Schorle H. Dual role of AP-2gamma in ErbB-2-induced mammary tumorigenesis. Breast Cancer Res Treat 2005, 90(3):273-280. 10.1007/s10549-004-4815-x, 15830141.
22. Richardson BD, Cheng YH, Langland RA, Handwerger S. Differential expression of AP-2gamma and AP-2alpha during human trophoblast differentiation. Life Sci 2001, 69(18):2157-2165. 10.1016/S0024-3205(01)01299-1, 11669459.
23. Bookout AL, Mangelsdorf DJ. Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nucl Recept Signal 2003, 1:e012. 10.1621/nrs.01012, 1402222, 16604184.
24. Chudin E, Kruglyak S, Baker SC, Oeser S, Barker D, McDaniel TK. A model of technical variation of microarray signals. J Comput Biol 2006, 13(4):996-1003. 10.1089/cmb.2006.13.996, 16761924.
25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545-15550. 10.1073/pnas.0506580102, 1239896, 16199517.
26. Nanni P, Pupa SM, Nicoletti G, De Giovanni C, Landuzzi L, Rossi I, Astolfi A, Ricci C, De Vecchi R, Invernizzi AM, et al. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 2000, 87(2):186-194. 10.1002/1097-0215(20000715)87:2<186::AID-IJC5>3.0.CO;2-1, 10861472.
27. Williams T, Tjian R. Characterization of a dimerization motif in AP-2 and its function in heterologous DNA-binding proteins. Science 1991, 251(4997):1067-1071. 10.1126/science.1998122, 1998122.
28. Zhu CH, Domann FE. Dominant negative interference of transcription factor AP-2 causes inhibition of ErbB-3 expression and suppresses malignant cell growth. Breast Cancer Res Treat 2002, 71(1):47-57. 10.1023/A:1013378113916, 11859873.
29. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995, 30(6):445-600. 10.3109/10409239509083491, 8770536.
30. Petraccia L, Onori P, Sferra R, Lucchetta MC, Liberati G, Grassi M, Gaudio E. [MDR (multidrug resistance) in hepatocarcinoma clinical-therapeutic implications]. Clin Ter 2003, 154(5):325-335.
31. Hishikawa K, Nakaki T, Fujii T. Connective tissue growth factor induces apoptosis via caspase 3 in cultured human aortic smooth muscle cells. Eur J Pharmacol 2000, 392(1-2):19-22. 10.1016/S0014-2999(00)00115-1, 10748267.
32. Hishikawa K, Oemar BS, Tanner FC, Nakaki T, Fujii T, Luscher TF. Overexpression of connective tissue growth factor gene induces apoptosis in human aortic smooth muscle cells. Circulation 1999, 100(20):2108-2112.
33. Szeto CC, Chow KM, Lai KB, Szeto CY, Kwan BC, Li PK. Connective tissue growth factor is responsible for transforming growth factor-beta-induced peritoneal mesothelial cell apoptosis. Nephron Exp Nephrol 2006, 103(4):e166-174. 10.1159/000092907, 16636587.
34. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE. Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer 2004, 11(4):781-791. 10.1677/erc.1.00825, 15613452.
35. Castro-Rivera E, Ran S, Brekken RA, Minna JD. Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells. Cancer Res 2008, 68(20):8295-8303. 10.1158/0008-5472.CAN-07-6601, 2760388, 18922901.
36. Castro-Rivera E, Ran S, Thorpe P, Minna JD. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci USA 2004, 101(31):11432-11437. 10.1073/pnas.0403969101, 509218, 15273288.
37. Chien W, Yin D, Gui D, Mori A, Frank JM, Said J, Kusuanco D, Marchevsky A, McKenna R, Koeffler HP. Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells. Mol Cancer Res 2006, 4(8):591-598. 10.1158/1541-7786.MCR-06-0029, 16877704.